Foghorn Therapeutics Inc. (FHTX) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
August 9, 2022 7:01 AM EDT- FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS
- On track to report initial Phase 1 clinical data for FHD-609 in synovial sarcoma in 2023
- Research milestone achieved under Merck collaboration in July, triggering $5 million milestone payment to Foghorn in the third quarter 2022
- Cash, cash equivalents and marketable securities of $394.7 million, as of June 30, 2022, provides significant cash runway
CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn®... More
